Technical analysis of TransCode Therapeutics, Inc. (RNAZ): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers.
Price Performance
| 1 month | -48.15% |
| 3 months | -64.26% |
| Year-to-date | -75.40% |
| 1 year | -85.21% |
| 3 years | -99.99% |
| 5 years | -100.00% |
52-Week Range
| 52-week High | $20.99 |
| 52-week Low | $1.58 |
| Avg Volume (90d) | 64K |
Technical Indicators
| SMA 50 | $4.42 |
| SMA 200 | $7.18 |
| Beta | 1.50 |
| 30-day Volatility (annualised) | 64.2% |
| Price vs SMA 50 | -62.0% |
| Price vs SMA 200 | -76.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $11.20 | |
| 2025-11 | $9.29 | -17.1% |
| 2025-12 | $6.83 | -26.5% |
| 2026-01 | $9.49 | +38.9% |
| 2026-02 | $9.61 | +1.3% |
| 2026-03 | $8.61 | -10.4% |
| 2026-04 | $8.01 | -7.0% |
| 2026-05 | $5.14 | -35.8% |
| 2026-06 | $6.21 | +20.8% |
| 2026-07 | $4.56 | -26.6% |
| 2026-08 | $2.10 | -53.9% |
| 2026-09 | $1.68 | -20.0% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | $0.04 | $67M |
| 2026-09-15 | | |
| 2026-09-15 | | $344M |
| 2026-09-15 | | |
Price
| Price | $1.68 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.01 |
| EV / EBITDA | 0.13 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.97 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -1.26 |